Jefferies Global Healthcare Conference
Logotype for MannKind Corporation

MannKind (MNKD) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for MannKind Corporation

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Growth outlook and commercial performance

  • Three growth engines for 2027: FUROSCIX ReadyFlow, Afrezza, and expanded United Therapeutics programs; nintedanib DPI represents a longer-term IPF opportunity.

  • Revenue CAGR was 42% over the past five years, driven by royalties, commercial collaboration revenue, FUROSCIX, and Afrezza; Q4 profitability and record revenue were expected.

  • Q4 revenue was forecast at ~$38 million, subject to quarter-end demand trends.

FUROSCIX ReadyFlow

  • ReadyFlow received approval in Q3; ~75% of FUROSCIX shipments had converted, while 90% of community demand prescriptions were for ReadyFlow.

  • Four target settings span worsening at home, emergency departments, inpatient IV diuretics, and post-discharge readmission; each represents nearly 1 million patients annually.

  • Hospital adoption had slowed, with expansion planned; inpatient discharge and readmission prevention were identified as major growth opportunities.

Afrezza and pediatric initiatives

  • Pediatric Afrezza adoption was strong: new-to-brand prescriptions rose 80%, about one in four patients at quarter-end were pediatric, and pediatric market share was 2x adult share in the first 90 days.

  • In 2027, plans include refocusing sales efforts on adults, expanding cardiovascular reach, and continuing pediatric support; a two-unit cartridge is also planned.

  • INHALE-1ST had ~35 participants; the goal is 100 by mid-2027 and a data readout, testing inhaled insulin in newly diagnosed children.

  • Inhale IQ, an inhaler adapter integrating dose tracking with CGM data, was being submitted to the FDA, with a launch targeted for 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from MannKind